Physician profile
Mark M Song
NPI 1326068560
$24,267.56
in general payments reported to CMS, 2019-2025
57 companies · $2,614 in 2025
The $2,614 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,638 · 2020: $3,491 · 2021: $3,962 · 2022: $3,452 · 2023: $3,149 · 2024: $2,963 · 2025: $2,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,652 · Education: $73.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,651.52 |
| Education | $73.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,183.62 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Amgen INC. | $2,887.80 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,007.00 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $1,297.83 | 2019-2024 | Linzess, Viberzi, Creon |
| Novo Nordisk INC | $1,289.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,199.18 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $875.24 | 2019-2023 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $800.53 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $727.90 | 2021-2025 | Veltassa, Korsuva |
| Takeda Pharmaceuticals U.S.A., INC. | $727.70 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $726.06 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $628.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $619.61 | 2022-2025 | |
| Gilead Sciences, INC. | $604.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $529.00 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $480.30 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Fresenius USA Marketing, INC. | $468.59 | 2019-2024 | Velphoro |
| Amarin Pharma, INC. | $402.81 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $393.26 | 2022-2025 | Tarpeyo |
| Pfizer INC. | $358.76 | 2019-2022 | |
| Radius Health, INC. | $290.21 | 2019-2025 | Tymlos |
| Allergan, INC. | $254.86 | 2019-2020 | |
| Eisai INC. | $228.48 | 2020-2021 | |
| Akebia Therapeutics INC | $217.16 | 2019-2024 | Vafseo, Auryxia |
| Ironwood Pharmaceuticals, INC | $203.88 | 2020-2024 | Linzess |
| Sanofi-Aventis U.S. LLC | $191.62 | 2019-2022 | |
| Vivus LLC | $185.52 | 2022-2024 | Pancreaze |
| Mallinckrodt Hospital Products INC. | $183.58 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $169.54 | 2021-2025 | Lupkynis |
| Dexcom, INC. | $103.01 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $100.12 | 2025 | Korlym |
| Ardelyx, INC. | $85.53 | 2024 | Ibsrela |
| Sumitomo Pharma America, INC. | $77.70 | 2023-2025 | Gemtesa |
| Shield Therapeutics INC | $75.54 | 2022 | |
| Opko Pharmaceuticals, LLC | $74.50 | 2019 | |
| Esperion Therapeutics, INC. | $64.79 | 2021-2024 | Nexletol |
| Nestle Healthcare Nutrition INC. | $63.79 | 2020-2021 | |
| Medtronic, INC. | $60.09 | 2021-2023 | Minimed 770g |
| Sunovion Pharmaceuticals INC. | $37.47 | 2022 | |
| Ibsa Pharma INC. | $34.47 | 2022-2023 | Tirosint, Licart |
| Exact Sciences Corporation | $30.44 | 2025 | Cologuard Collection Kit |
| Mannkind Corporation | $29.64 | 2021 | |
| Boston Scientific Corporation | $28.13 | 2023 | Superion Indirect Decompression System |
| Kyowa Kirin, INC. | $27.09 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.32 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $23.92 | 2024 | |
| Travere Therapeutics, INC. | $23.05 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $23.01 | 2019 | |
| Edwards Lifesciences Corporation | $22.17 | 2020 | |
| Zealand Pharma US, INC. | $20.62 | 2021 | |
| Abbott Laboratories | $18.20 | 2023 | Freestyle Libre 3 |
| Almatica Pharma LLC | $17.68 | 2023 | Loreev Xr |
| Mallinckrodt Enterprises LLC | $17.19 | 2019 | |
| Scpharmaceuticals INC. | $15.27 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.42 | 2020 | |
| Redhill Biopharma INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.